Pyxis Oncology, Inc. SEC filings PYXS
Pyxis Oncology, Inc. has 356 filings in SEC EDGAR's recent list, going back to Jul 12, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 23, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 18, 2025 | Dec 31, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 10-K/A | Amended annual report | May 10, 2023 | Dec 31, 2022 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 22, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 29, 2022 | Dec 31, 2021 |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PYXS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1782223
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.